Filters








21 Hits in 12.6 sec

Identifying drug-related attributes to personalise antihypertensive agents: the outcome report of patients receiving metoprolol therapy

Chunyu Liu, Jing Xu, Ran Liu, Miye Wang, Yixuan Zhuo, Lan Su, Hongmei Yan, Qing Zhang
2021 BMC Medical Informatics and Decision Making  
Conclusion Our study showed that all metoprolol-related attributes identified are reasonable and helpful in improving the personalisation of metoprolol therapy.  ...  Methods We collected clinical data on attributes related to hypertension and its therapy of inpatients from West China Hospital who received metoprolol therapy and constructed the sensitive spectrum using  ...  Only a few attributes are significantly related or sensitive to the outcomes of patients with hypertension receiving metoprolol monotherapy, and we classified them as 'metoprolol-related attributes' .  ... 
doi:10.1186/s12911-021-01739-9 pmid:34969399 pmcid:PMC8717677 fatcat:grwinanyajcovnawhwcf74mc5u

Drug Interactions, Pharmacogenomics and Cardiovascular Complication [chapter]

Irina Piatkov, Trudi Jones, Mark McLe
2013 Drug Discovery  
Conclusion Adverse drug reactions ADRs have been reported to be the cause for drug withdrawal after marketing, hospital admissions, death in hospitalised patients and to be the fourth leading cause of  ...  This finding led to the development of a novel antihypertensive drug class targeting adducin [ , ] .  ...  ] Preskorn SH Relating clinical trials to psychiatric practice part I the case of a -year old on aripiprazole and fluoxetine. J Psychiatr Pract -  ... 
doi:10.5772/48423 fatcat:kezkydyy6jesjbm6fpo5n7ihtq

The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O. board

Maurizio Rolando, Emilia Cantera, Rita Mencucci, Pierangela Rubino, Pasquale Aragona
2017 International ophtalmology  
The discussion centred on the appropriate definition of TD, proposing a new classification of risk factors and how to identify them, how to make a correct diagnosis choosing the rational therapy (questionnaires  ...  elements involved), which artificial tear matches the ideal profile for a rational therapy and which questions should be done to the patient.  ...  Compliance with ethical standards Conflict of interest The authors report no conflicts of interest in this work.  ... 
doi:10.1007/s10792-017-0524-4 pmid:28397148 pmcid:PMC5932107 fatcat:lv2jgm2z7bfnnkawhtciv3jibm

Interventions in Pregnancy to Reduce Risk of Stillbirth [chapter]

Alexander Heazell, Vicki Flenady
2019 Fetal Therapy  
related to their diabetes, such as depression and adverse effects on quality of life.  ...  However, helping patients to modify certain behaviours should take account of other factors such as the patient's willingness to change, their perception of their diabetes, and factors which may be indirectly  ...  ) (HR 0.86, CI 0.76 to 0.98, p=0.026). 414 his study is also included in a meta-analysis of eight trials comparing beta blockers and other antihypertensive agents on cardiovascular outcomes which showed  ... 
doi:10.1017/9781108564434.006 fatcat:rynlluzyr5fajiwmkjub3w6rze

Abstracts from the American College of Clinical Pharmacy 2015 Global Conference on Clinical Pharmacy - Scientific

2015 Pharmacotherapy  
Secondary outcomes include the prevalence of attaining target troughs, attaining combined peak and trough targets, the incidence of nephrotoxicity, and identifying factors impacting levels.  ...  The primary objective is to evaluate the efficacy of the CF dosing nomogram in attaining therapeutic peaks based on the initial regimen.  ...  Each array consisted of the unbound C max resulting from the highest clinical dose according to the respective patient package insert.  ... 
doi:10.1002/phar.1659 fatcat:sbyxfr37ijdbrkklp7te7jg7ya

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim (+72 others)
2012 European Heart Journal  
alone may be sufficient for patients with mildly elevated BP, and should always be advised for patients receiving antihypertensive drugs as they may reduce the dosage of antihypertensives needed to achieve  ...  After 1 year, ,50% of patients report persistent use of statins, beta-blockers, or antihypertensive therapy. 518, 519 The reasons for poor adherence are multifactorial.  ... 
doi:10.1093/eurheartj/ehs092 pmid:22555213 fatcat:jnpffsiywvbztl3igaqkaqcpuy

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018

John J. Atherton, Andrew Sindone, Carmine G. De Pasquale, Andrea Driscoll, Peter S. MacDonald, Ingrid Hopper, Peter M. Kistler, Tom Briffa, James Wong, Walter Abhayaratna, Liza Thomas, Ralph Audehm (+4 others)
2018 Heart, Lung and Circulation  
antagonists), beta blockers, statins, and/or antihypertensive therapy (or blood pressure lowering) improves clinical outcomes?  ...  A minority of patients develop LV systolic dysfunction in response to dyssynchrony attributable to RV pacing.  ... 
doi:10.1016/j.hlc.2018.06.1042 pmid:30077227 fatcat:rk4enhh5aveefiqtwxvhrpylru

Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment – systematic review and modelling of progression and cost-effectiveness

Andrew J Farmer, Richard Stevens, Jennifer Hirst, Tom Lung, Jason Oke, Philip Clarke, Paul Glasziou, Andrew Neil, David Dunger, Helen M Colhoun, Christopher Pugh, Germain Wong (+2 others)
2014 Health Technology Assessment  
Data from systematically identified randomised trials reporting the impact on renal outcomes of angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers for type 1 and type 2 diabetes  ...  Individual patient data for type 1 and type 2 diabetes patients were used to obtain parameters describing progression and variability of measurement over time for the albumin-to-creatinine ratio (ACR)  ...  intervals for monitoring This monograph presents this work and discusses the implications of these findings for the work Systematic review protocol: Impact of antihypertensive agents on outcomes of diabetic  ... 
doi:10.3310/hta18140 pmid:24576414 pmcid:PMC4781444 fatcat:36uon2or7nedfnt37nowdmpmhm

Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease

Michele Massimo Gulizia, Furio Colivicchi, Maurizio Giuseppe Abrignani, Marco Ambrosetti, Nadia Aspromonte, Gabriella Barile, Roberto Caporale, Giancarlo Casolo, Emilia Chiuini, Andrea Di Lenarda, Pompilio Faggiano, Domenico Gabrielli (+103 others)
2018 European Heart Journal, Supplement  
The authors declare they have no conflict of interests.  ...  It remains to be seen whether the optimisation of DAPT using the new antithrombotic drugs can help improve the outcome of these patients.  ...  antithrombotic drugs: interaction between factors related to the patient, medication and the quality of care Drugs Patient Quality of care • Potency, dosage • Bioavailability • Elimination •  ... 
doi:10.1093/eurheartj/suy019 pmid:29867293 pmcid:PMC5978022 fatcat:bsnf3y3t3ne6xcxbcrc6s64qcm

Multimedia educational interventions for consumers about prescribed and over-the-counter medications

Sabina Ciciriello, Renea V Johnston, Richard H Osborne, Ian Wicks, Tanya deKroo, Rosemary Clerehan, Clare O'Neill, Rachelle Buchbinder
2013 The Cochrane library  
Aim of the intervention: To enhance compliance with prescribed drug therapy.  ...  Patients eligible for oral anticoagulant therapy received a standard explanation of the need for this therapy and its risk/benefits.  ...  Each pill was labelled with the day, the number of the pill and instructions relating to when to take the pill and how long to wait until eating Usual care (verbal instructions) Received a standard set  ... 
doi:10.1002/14651858.cd008416.pub2 pmid:23633355 fatcat:j263opbpdrhvxbn5yboax4ovye

The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003

David K McKenzie, Peter A Frith, Jonathan G W Burdon, G Ian Town, Australian Lung Foundation, Thoracic Society of Australia and New Zealand
2003 Medical Journal of Australia  
What the patient needs to know  Patients receiving oxygen therapy in the home, and their carers, should have the use clearly explained.  ...  The difference in clinical presentation and therapeutic interventions received reported by Andell's group, may partially explain the discrepant outcomes seen in COPD patients (COPD patients were more likely  ...  Long term oxygen therapy (McDonald et al., 2005)  ... 
pmid:12633498 fatcat:5phpt43gqvd5pnwxmm5c5q3slu

Abstract Book of the 19th European Congress in Internal Medicine

Authors of ECIM, Lorella La Leggia
2021 European Journal of Case Reports in Internal Medicine  
Book of the 19th European Congress in Internal Medicine Internal Medicine in a Pandemic World: When One Size Fits All  ...  Methods: We report the cases of 2 patients who present with severe scleromyositis requiring immunoglobilins.  ...  Considering the severity of the myogenic impairment and the associated scleroderma, the patient received ivig 2 g/kg/4 weeks + 15 mg corticosteroids + 2.5 mg/kg/d azathioprine with an excellent evolution  ... 
doi:10.12890/2021_v8sup1 fatcat:yhv57saisvfefa5ode4ptgncgm

Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia

Emily Banks, Simon R Crouch, Rosemary J Korda, Bill Stavreski, Karen Page, Katherine A Thurber, Robert Grenfell
2016 Medical Journal of Australia  
Another method is to base the defi cit on reported usual intake, although this is less accurate due to patient under-reporting of intake.  ...  The majority of people with diabetes will require more than one antihypertensive agent in order to achieve acceptable cardiovascular risk reduction.  ... 
doi:10.5694/mja15.01004 pmid:27125809 fatcat:y7yn4oeq4jgt3j53opj3p6wxbu

LC-MS/MS measurement of parathyroid hormone PTH (1-34): Use in studying oral PTH (1-34) administration and possible diagnostic application in pseudohypoparathyroidism

Sulaiman Al-Riyami, Jonathan Tang, Hillel Galitzer, William Fraser
2017 Endocrine Abstracts  
The abstracts submitted were marked by the Abstract Marking panel selected by the Programme Committee.  ...  patients receiving carbimazole and metoprolol succinate 25-50 mg/day).  ...  Results The mean age of patients receiving denosumab therapy was 71.5 years.  ... 
doi:10.1530/endoabs.50.p042 fatcat:mlqefg6jxbevjcab3eid4sfxpy

Abstracts

2016 Acta Physiologica  
As 75% of patients are with at least one missense allele, the potential of 4-PBA (an FDA-approved drug) seems to be a promising strategy for allele-specific therapy of ABCC6-associated calcification disorders  ...  Exercise tolerance is determined by the ability to minimize the rate at which metabolic acidaemia and related contributors to fatigue develop.  ...  We aimed to compare MDSPCs with bone marrow mesenchymal stem cells (BM-MSCs) and to evaluate their feasibility for the treatment of AKI.  ... 
doi:10.1111/apha.12712 pmid:27329970 fatcat:imcxhh3singqdlh7umt4tcj54y
« Previous Showing results 1 — 15 out of 21 results